EUVIMEDEUVIMED entdecken
Metaanalyse

2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis

JIA YAO, MEILING WANG, YUSEN DING, GANG GUO, LIN LI, LEI ZHANG

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2732-lb ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von JIA YAO und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: GLP-1 RAs confer cardiovascular and metabolic benefits, but their specific impact on DFU risk remains unclear. This meta-analysis systematically evaluated the association between GLP-1 RA therapy and incident DFUs, along with secondary outcomes of lower limb amputation (LLA), DFU-related hospitalization, and all-cause mortality in adults with T2DM.

Methods

Following PRISMA guidelines, we searched PubMed, Embase, Cochrane Library, and Web of Science. Eligible studies included randomized controlled trials (RCTs) and observational cohort studies comparing GLP-1 RAs with other glucose-lowering therapies. Two reviewers independently screened studies, extracted data, and assessed bias using Cochrane RoB 2 (RCTs) and the Newcastle-Ottawa Scale (observational studies). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated via random-effects models. Subgroup analyses were stratified by treatment duration (≤400 vs. >400 days) and GLP-1 RA subtype (short- vs. long-acting). Sensitivity analyses and Egger’s test were performed to verify robustness.

Results

We included 31 studies (18 RCTs and 13 cohorts) encompassing 826,412 T2DM patients were included. GLP-1 RA use was associated with an 19% lower risk of incident DFUs compared with controls (pooled HR = 0.81, 95% CI: 0.74-0.89, p < 0.001). Long-term use (>400 days) yielded stronger protection (HR = 0.74, 95% CI: 0.66-0.83) than short-term use (HR = 0.88, 95% CI: 0.79-0.98). GLP-1 RAs also significantly reduced LLA (HR = 0.72, 95% CI: 0.61-0.85), DFU-related hospitalization (HR = 0.78, 95% CI: 0.70-0.87), and all-cause mortality (HR = 0.85, 95% CI: 0.79-0.92; all p < 0.001). Heterogeneity was moderate (I² = 58%), and no significant publication bias was detected (Egger’s test p = 0.23).

Conclusion

GLP-1 RA therapy significantly reduces the risk of DFUs and related complications in T2DM patients. These results support the clinical application of GLP-1 RAs among patients with DFU. Further large-scale trials are needed to verify causality and optimal regimens. Disclosure J. Yao: None. M. Wang: None. Y. Ding: None. G. Guo: None. L. Li: None. L. Zhang: None.

Zitieren

APA

YAO, J., WANG, M., DING, Y., GUO, G., LI, L., & ZHANG, L. (2026). 2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2732-lb

Vancouver

YAO J, WANG M, DING Y, GUO G, LI L, ZHANG L. 2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2732-lb

BibTeX
@article{YAO2026,
  author = {YAO, JIA and WANG, MEILING and DING, YUSEN and GUO, GANG and LI, LIN and ZHANG, LEI},
  title = {2732-LB: GLP-1 Receptor Agonists and Diabetic Foot Ulcer Risk: A Meta-analysis},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2732-lb}
}
Kostenlos starten →